• About
  • Subscribe
  • Advertise
  • Contact
Tuesday, June 24, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

Optometry Australia report: $50m in savings if optometrists authorised for oral prescribing  

by Staff Writer
February 7, 2025
in Associations, Eye disease, Local, News, Ophthalmic insights, Optometrists, Policy & regulation, Regulators, Workforce
Reading Time: 6 mins read
A A
Optometry Australia is advocating that optometrists be allowed to administer some medicines. Image: doucefleur/stock.adobe.com.

Optometry Australia is advocating that optometrists be allowed to administer some medicines. Image: doucefleur/stock.adobe.com.

Share on FacebookShare on Twitter

A new report says allowing optometrists to prescribe oral medicines for ocular conditions could save the Australian health budget $50 million a year. 

The analysis is to be shared with federal and state health ministers as part of Optometry Australia’s (OA) push for change on the profession’s scope-of-practice. 

The organisation is also calling on the Optometry Board of Australia (OBA) to take action to review and change rules around the use of schedule medicines. 

With optometrists able to prescribe oral drugs in other countries with similar health systems, OA has long advocated for this change. However, the move is not supported by the entire industry, with both RANZCO and the Australian Society of Ophthalmologists previously telling Insight they oppose this scope change, stating optometrists don’t have the appropriate medical training and experience, which could compromise patient safety. 

RANZCO did not wish to comment on this latest announcement.

The report, The Value of Expanding Optometrists’ Prescribing Rights in Australia, prepared by HTANALYSTS and commissioned by OA, is an economic analysis of common cases of ocular conditions such as severe dry eye, herpes zoster ophthalmicus, and preseptal cellulitis. 

It outlines health budget savings of around $50 million per year, patient savings of approximating $27m million per year, and significant improvements to productivity and access to care through optometrist oral prescribing.  

 The report also said that allowing optometrists to prescribe oral medicines would mean time savings for ophthalmologists by reducing “unnecessary onward referrals”. 

  It compares the patient journey, system and patient costs, professional time saved, and productivity implications of treating various ocular conditions currently and into the future, enabled by optometrist oral prescribing.  

 Key highlights of the analysis include:  

  • Treatment of severe dry eye by optometrists with oral medicines has the potential to save over 700,000 GP visits per year, equating to over $30 million of federal funding, and $8 million of patient incurred expenses, in addition to almost 200,000 ophthalmology appointments being saved for more critical conditions.  
  • Oral prescribing by optometrists to treat herpes zoster ophthalmicus has the potential to alleviate $663,000 of avoided productivity costs. 
  • Treatment of acute angle closure glaucoma by optometrists, when a patient does not have appropriate access to emergency ophthalmologist care, would not only improve visual outcomes, but would also save around $8500 per patient in treatment costs. 

An OA media release said the Federal Government’s Scope of Practice Review – Unleashing the Potential of our Health Workforce – had acknowledged that there is “strong evidence of improved consumer access to care, consumer experience of care and health outcomes when health professionals are enabled to work to full scope-of-practice”.  

OA has also released a Position Statement on Medicines, outlining its position on the prescribing of medicines by optometrists.  

It has called on that the OBA to “take action to review and contemporise the Guidelines for the Use of Scheduled Medicines, to enable therapeutically endorsed optometrists to prescribe oral medications for the purpose of practising optometry”. 

 “Australia’s approximately 7,000 optometrists currently face significantly more limitations to their scope-of-practice than their counterparts with similar training in other countries,” OA said. 

“This includes the United Kingdom (prescribing since 2008), New Zealand (since 2014) and the United States (in all 50 states, the first of which commenced oral prescribing in 1977).” 

In response to the new report, OA CEO Ms Skye Cappuccio said: “Oral and topical prescribing are within the current level of training and knowledge of therapeutically qualified Australian optometrists, so it is imperative that relevant regulations should allow therapeutically endorsed optometrists to prescribe medications for the purpose of practising optometry. 

“This is in the best interests of their patients and will bring significant improvements to our overburdened healthcare system.” 

More reading

A hard pill to swallow: oral medication prescribing rights for optometrists

Expanded scope only way to tackle eye health issues, OA says

MBS Taskforce keeps controversial eye injection proposals in final report

Related Posts

Cyber attackers are often driven by financial gain, with healthcare practices considered a lucrative target. Image: Lee Charlie/Shutterstock.com.

Don’t be blindsided by a cyber attack

by Staff Writer
June 24, 2025

Interruptions to service delivery and reputational damage are consequences of cyber attacks, which means cyber security should be a top...

Optometrist Michael Young’s daughter, a fourth-year optometry student at QUT, undergoing a visual field test on the VF2000 NEO. Image: Michael Young.

Perimetry remastered with VR device from BOC Instruments

by Staff Writer
June 24, 2025

A Californian-made virtual-reality visual field device has been on the wish list of many Australian optometry practice owners thanks to...

The 2025 meeting is taking place in Melbourne 14-17 November. Image: f11photo/stock.adobe.come & Prime Creative Media.

RANZCO has sights on biggest congress yet in 2025

by Staff Writer
June 24, 2025

RANZCO is anticipating its 2025 congress in Melbourne may be one of the largest yet. Since opening registration on 10...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited